The safety profile of IkT-148009, an investigational oral medication for Parkinson’s disease, improved the longer the drug was dosed, demonstrating target selectivity, according to interim three-month animal data. The ongoing toxicology studies, conducted by the therapy’s developer, Inhibikase Therapeutics, were designed to meet regulatory requirements for regular…
Current understanding of Parkinson’s disease does not reflect patients from diverse socioeconomic or ethnic backgrounds, and they remain poorly represented in research, according to a position paper from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). “The current picture of PD [Parkinson’s disease] has been assembled from…
MedRhythms, which is pioneering rhythmic auditory stimulation to improve walking ability in people with neurological disorders, has now launched a partnership with Universal Music Group (UMG) — owner of a vast catalog of recordings and songs — to expand its prescription music offerings to patients. The collaboration will allow…
The Parkinson Voice Project (PVP) is hosting its second annual Parkinson’s Virtual Choir Concert on Nov. 6, with more than 300 Parkinson’s disease patients from around the world and their family members and friends taking part. The online event, which can be viewed on the PVP website, will feature…
nQ Medical and EvergreenHealth are looking for people with early stage Parkinson’s disease to enter a monthlong study of a software tool — known as neuroQWERTY — to help track motor symptoms by monitoring how fingers interact with a computer’s keyboard. The study, expected to start in July, will enroll about 50…
Immune cells in the brain responsible for breaking down the toxic protein clumps, or aggregates, that lead to nerve cell death in Parkinson’s disease join together to form networks to share the burden, a study showed for the first time. These networked cells also share energy-producing mitochondria to help…
The activity of the enzyme glucocerebrosidase, called GCase, is not tied to the risk of developing Parkinson’s, nor linked with the disease’s severity, a new analysis from Israel indicates. “We did not find an association with risk for” the early signs or symptoms of Parkinson’s disease, the researchers wrote,…
Hartford Healthcare has been awarded a Parkinson Voice Project 2021 SPEAK OUT! & LOUD Crowd grant — which the Connecticut healthcare network will use to expand its speech therapy programs. Each clinic awarded one of the more than 200 global SPEAK OUT! & LOUD Crowd grants receives therapy…
A new Phase 2 clinical trial will test the psychedelic painkiller ketamine as a treatment for levodopa-induced dyskinesia in people with Parkinson’s disease. The trial, called KET-LID (NCT04912115), is expected to start enrolling participants this month. The first results are expected by the end of the year. Launched by …
Amprion has announced the commercial rollout of SYNTap Biomarker Test, a laboratory test to accurately detect alpha-synuclein aggregates, a hallmark of various brain diseases, including Parkinson’s disease. Alpha-synuclein, a protein, can misfold and accumulate (aggregate) in toxic clumps called Lewy bodies, leading to the death of nerve…
Get regular updates to your inbox.